This article was originally published in The Tan Sheet
Valeant buys Brazilian nutrition firm Probiotica; Nutraceutical International keeps up acquisitions; Claritin weighs on Merck consumer in Q4; J&J acetaminophen study backs Glaxo; more news In Brief.
You may also be interested in...
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
GlaxoSmithKline generated clinical data supporting the greater pain-relief efficacy of 1,000 mg of acetaminophen over 500-mg and 650-mg doses, urging FDA to maintain OTC status for the high dose.
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.